APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oligodendroglioma Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Research

Oligodendroglioma Treatment Industry Research Report 2026

22 December 2025132 pages

Choose your research edition.

Industry ResearchOligodendroglioma Treatment Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Oligodendroglioma Treatment Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Oligodendroglioma Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oligodendroglioma Treatment Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Oligodendroglioma Treatment Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Oligodendroglioma Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Oligodendroglioma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Oligodendroglioma Treatment is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Oligodendroglioma Treatment is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Oligodendroglioma Treatment include Novartis AG, F. Hoffmann-La Roche Ltd, Eli Lilly and Co, Pfizer Inc, Tocagen Inc, Northwest Biotherapeutics Inc, Millennium Pharmaceuticals Inc, Leadiant Biosciences Inc and Ipsen SA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Oligodendroglioma Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Oligodendroglioma Treatment Market by Company

Novartis AG

F. Hoffmann-La Roche Ltd

Eli Lilly and Co

Pfizer Inc

Tocagen Inc

Northwest Biotherapeutics Inc

Millennium Pharmaceuticals Inc

Leadiant Biosciences Inc

Ipsen SA

Immatics Biotechnologies GmbH

Celldex Therapeutics Inc

Cavion LLC

Bristol-Myers Squibb Co

Boehringer Ingelheim GmbH

AngioChem Inc

Oligodendroglioma Treatment Segment by Type

Dasatinib

Bevacizumab

IMA-950

DCVax-L

CDX-1401

Alisertib

Others

Oligodendroglioma Treatment Segment by Application

ASCs

Hospital

Clinic

Oligodendroglioma Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligodendroglioma Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oligodendroglioma Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligodendroglioma Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Oligodendroglioma Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Oligodendroglioma Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Oligodendroglioma Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Oligodendroglioma Treatment Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Oligodendroglioma Treatment Sales (k units) of Manufacturers (2021-2026) Table 7. Global Oligodendroglioma Treatment Sales Market Share by Manufacturers (2021-2026) Table 8. Global Oligodendroglioma Treatment Revenue of Manufacturers (2021-2026) Table 9. Global Oligodendroglioma Treatment Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Oligodendroglioma Treatment Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Oligodendroglioma Treatment Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Oligodendroglioma Treatment, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Oligodendroglioma Treatment, Product Type & Application Table 14. Global Oligodendroglioma Treatment Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Oligodendroglioma Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Novartis AG Company Information Table 19. Novartis AG Business Overview Table 20. Novartis AG Oligodendroglioma Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Novartis AG Oligodendroglioma Treatment Product Portfolio Table 22. Novartis AG Recent Developments Table 23. F. Hoffmann-La Roche Ltd Company Information Table 24. F. Hoffmann-La Roche Ltd Business Overview Table 25. F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Product Portfolio Table 27. F. Hoffmann-La Roche Ltd Recent Developments Table 28. Eli Lilly and Co Company Information Table 29. Eli Lilly and Co Business Overview Table 30. Eli Lilly and Co Oligodendroglioma Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Eli Lilly and Co Oligodendroglioma Treatment Product Portfolio Table 32. Eli Lilly and Co Recent Developments Table 33. Pfizer Inc Company Information Table 34. Pfizer Inc Business Overview Table 35. Pfizer Inc Oligodendroglioma Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Pfizer Inc Oligodendroglioma Treatment Product Portfolio Table 37. Pfizer Inc Recent Developments Table 38. Tocagen Inc Company Information Table 39. Tocagen Inc Business Overview Table 40. Tocagen Inc Oligodendroglioma Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Tocagen Inc Oligodendroglioma Treatment Product Portfolio Table 42. Tocagen Inc Recent Developments Table 43. Northwest Biotherapeutics Inc Company Information Table 44. Northwest Biotherapeutics Inc Business Overview Table 45. Northwest Biotherapeutics Inc Oligodendroglioma Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Northwest Biotherapeutics Inc Oligodendroglioma Treatment Product Portfolio Table 47. Northwest Biotherapeutics Inc Recent Developments Table 48. Millennium Pharmaceuticals Inc Company Information Table 49. Millennium Pharmaceuticals Inc Business Overview Table 50. Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Product Portfolio Table 52. Millennium Pharmaceuticals Inc Recent Developments Table 53. Leadiant Biosciences Inc Company Information Table 54. Leadiant Biosciences Inc Business Overview Table 55. Leadiant Biosciences Inc Oligodendroglioma Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Leadiant Biosciences Inc Oligodendroglioma Treatment Product Portfolio Table 57. Leadiant Biosciences Inc Recent Developments Table 58. Ipsen SA Company Information Table 59. Ipsen SA Business Overview Table 60. Ipsen SA Oligodendroglioma Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Ipsen SA Oligodendroglioma Treatment Product Portfolio Table 62. Ipsen SA Recent Developments Table 63. Immatics Biotechnologies GmbH Company Information Table 64. Immatics Biotechnologies GmbH Business Overview Table 65. Immatics Biotechnologies GmbH Oligodendroglioma Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Immatics Biotechnologies GmbH Oligodendroglioma Treatment Product Portfolio Table 67. Immatics Biotechnologies GmbH Recent Developments Table 68. Celldex Therapeutics Inc Company Information Table 69. Celldex Therapeutics Inc Business Overview Table 70. Celldex Therapeutics Inc Oligodendroglioma Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Celldex Therapeutics Inc Oligodendroglioma Treatment Product Portfolio Table 72. Celldex Therapeutics Inc Recent Developments Table 73. Cavion LLC Company Information Table 74. Cavion LLC Business Overview Table 75. Cavion LLC Oligodendroglioma Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Cavion LLC Oligodendroglioma Treatment Product Portfolio Table 77. Cavion LLC Recent Developments Table 78. Bristol-Myers Squibb Co Company Information Table 79. Bristol-Myers Squibb Co Business Overview Table 80. Bristol-Myers Squibb Co Oligodendroglioma Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Bristol-Myers Squibb Co Oligodendroglioma Treatment Product Portfolio Table 82. Bristol-Myers Squibb Co Recent Developments Table 83. Boehringer Ingelheim GmbH Company Information Table 84. Boehringer Ingelheim GmbH Business Overview Table 85. Boehringer Ingelheim GmbH Oligodendroglioma Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Boehringer Ingelheim GmbH Oligodendroglioma Treatment Product Portfolio Table 87. Boehringer Ingelheim GmbH Recent Developments Table 88. AngioChem Inc Company Information Table 89. AngioChem Inc Business Overview Table 90. AngioChem Inc Oligodendroglioma Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. AngioChem Inc Oligodendroglioma Treatment Product Portfolio Table 92. AngioChem Inc Recent Developments Table 93. Global Oligodendroglioma Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Oligodendroglioma Treatment Sales by Region (2021-2026) & (k units) Table 95. Global Oligodendroglioma Treatment Sales Market Share by Region (2021-2026) Table 96. Global Oligodendroglioma Treatment Sales by Region (2027-2032) & (k units) Table 97. Global Oligodendroglioma Treatment Sales Market Share by Region (2027-2032) Table 98. Global Oligodendroglioma Treatment Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Oligodendroglioma Treatment Revenue Market Share by Region (2021-2026) Table 100. Global Oligodendroglioma Treatment Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Oligodendroglioma Treatment Revenue Market Share by Region (2027-2032) Table 102. North America Oligodendroglioma Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Oligodendroglioma Treatment Sales by Country (2021-2026) & (k units) Table 104. North America Oligodendroglioma Treatment Sales by Country (2027-2032) & (k units) Table 105. North America Oligodendroglioma Treatment Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Oligodendroglioma Treatment Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Oligodendroglioma Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Oligodendroglioma Treatment Sales by Country (2021-2026) & (k units) Table 109. Europe Oligodendroglioma Treatment Sales by Country (2027-2032) & (k units) Table 110. Europe Oligodendroglioma Treatment Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Oligodendroglioma Treatment Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Oligodendroglioma Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Oligodendroglioma Treatment Sales by Country (2021-2026) & (k units) Table 114. Asia Pacific Oligodendroglioma Treatment Sales by Country (2027-2032) & (k units) Table 115. Asia Pacific Oligodendroglioma Treatment Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Oligodendroglioma Treatment Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Oligodendroglioma Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Oligodendroglioma Treatment Sales by Country (2021-2026) & (k units) Table 119. South America Oligodendroglioma Treatment Sales by Country (2027-2032) & (k units) Table 120. South America Oligodendroglioma Treatment Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Oligodendroglioma Treatment Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Oligodendroglioma Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Oligodendroglioma Treatment Sales by Country (2021-2026) & (k units) Table 124. Middle East and Africa Oligodendroglioma Treatment Sales by Country (2027-2032) & (k units) Table 125. Middle East and Africa Oligodendroglioma Treatment Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Oligodendroglioma Treatment Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Oligodendroglioma Treatment Sales by Type (2021-2026) & (k units) Table 128. Global Oligodendroglioma Treatment Sales by Type (2027-2032) & (k units) Table 129. Global Oligodendroglioma Treatment Sales Market Share by Type (2021-2026) Table 130. Global Oligodendroglioma Treatment Sales Market Share by Type (2027-2032) Table 131. Global Oligodendroglioma Treatment Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Oligodendroglioma Treatment Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Oligodendroglioma Treatment Revenue Market Share by Type (2021-2026) Table 134. Global Oligodendroglioma Treatment Revenue Market Share by Type (2027-2032) Table 135. Global Oligodendroglioma Treatment Price by Type (2021-2026) & (US$/unit) Table 136. Global Oligodendroglioma Treatment Price by Type (2027-2032) & (US$/unit) Table 137. Global Oligodendroglioma Treatment Sales by Application (2021-2026) & (k units) Table 138. Global Oligodendroglioma Treatment Sales by Application (2027-2032) & (k units) Table 139. Global Oligodendroglioma Treatment Sales Market Share by Application (2021-2026) Table 140. Global Oligodendroglioma Treatment Sales Market Share by Application (2027-2032) Table 141. Global Oligodendroglioma Treatment Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Oligodendroglioma Treatment Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Oligodendroglioma Treatment Revenue Market Share by Application (2021-2026) Table 144. Global Oligodendroglioma Treatment Revenue Market Share by Application (2027-2032) Table 145. Global Oligodendroglioma Treatment Price by Application (2021-2026) & (US$/unit) Table 146. Global Oligodendroglioma Treatment Price by Application (2027-2032) & (US$/unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Oligodendroglioma Treatment Distributors List Table 150. Oligodendroglioma Treatment Customers List Table 151. Oligodendroglioma Treatment Industry Trends Table 152. Oligodendroglioma Treatment Industry Drivers Table 153. Oligodendroglioma Treatment Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Oligodendroglioma Treatment Product Image Figure 5. Global Oligodendroglioma Treatment Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Oligodendroglioma Treatment Market Size (2021-2032) & (US$ Million) Figure 7. Global Oligodendroglioma Treatment Sales (2021-2032) & (k units) Figure 8. Global Oligodendroglioma Treatment Average Price (US$/unit) & (2021-2032) Figure 9. Dasatinib Product Image Figure 10. Bevacizumab Product Image Figure 11. IMA-950 Product Image Figure 12. DCVax-L Product Image Figure 13. CDX-1401 Product Image Figure 14. Alisertib Product Image Figure 15. Others Product Image Figure 16. ASCs Product Image Figure 17. Hospital Product Image Figure 18. Clinic Product Image Figure 19. Global Oligodendroglioma Treatment Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Oligodendroglioma Treatment, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Oligodendroglioma Treatment Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Oligodendroglioma Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Oligodendroglioma Treatment Sales by Region in 2025 Figure 25. Global Oligodendroglioma Treatment Revenue by Region in 2025 Figure 26. North America Oligodendroglioma Treatment Market Size by Country in 2025 Figure 27. North America Oligodendroglioma Treatment Sales Market Share by Country (2021-2032) Figure 28. North America Oligodendroglioma Treatment Revenue Market Share by Country (2021-2032) Figure 29. United States Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Mexico Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Europe Oligodendroglioma Treatment Market Size by Country in 2025 Figure 33. Europe Oligodendroglioma Treatment Sales Market Share by Country (2021-2032) Figure 34. Europe Oligodendroglioma Treatment Revenue Market Share by Country (2021-2032) Figure 35. Germany Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. France Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. U.K. Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Italy Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Russia Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Spain Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Netherlands Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Switzerland Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Sweden Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Poland Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Asia Pacific Oligodendroglioma Treatment Market Size by Country in 2025 Figure 46. Asia Pacific Oligodendroglioma Treatment Sales Market Share by Country (2021-2032) Figure 47. Asia Pacific Oligodendroglioma Treatment Revenue Market Share by Country (2021-2032) Figure 48. China Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Japan Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South Korea Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. India Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Australia Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Taiwan Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. South America Oligodendroglioma Treatment Market Size by Country in 2025 Figure 57. South America Oligodendroglioma Treatment Sales Market Share by Country (2021-2032) Figure 58. South America Oligodendroglioma Treatment Revenue Market Share by Country (2021-2032) Figure 59. Brazil Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Argentina Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Chile Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Colombia Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Middle East and Africa Oligodendroglioma Treatment Market Size by Country in 2025 Figure 64. Middle East and Africa Oligodendroglioma Treatment Sales Market Share by Country (2021-2032) Figure 65. Middle East and Africa Oligodendroglioma Treatment Revenue Market Share by Country (2021-2032) Figure 66. Egypt Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. South Africa Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Israel Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Türkiye Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. GCC Countries Oligodendroglioma Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 71. Global Oligodendroglioma Treatment Sales Market Share by Type (2021-2032) Figure 72. Global Oligodendroglioma Treatment Revenue Market Share by Type (2021-2032) Figure 73. Global Oligodendroglioma Treatment Price (US$/unit) by Type (2021-2032) Figure 74. Global Oligodendroglioma Treatment Sales Market Share by Application (2021-2032) Figure 75. Global Oligodendroglioma Treatment Revenue Market Share by Application (2021-2032) Figure 76. Global Oligodendroglioma Treatment Price (US$/unit) by Application (2021-2032) Figure 77. Oligodendroglioma Treatment Value Chain Figure 78. Oligodendroglioma Treatment Production Mode & Process Figure 79. Direct Comparison with Distribution Share Figure 80. Distributors Profiles Figure 81. Oligodendroglioma Treatment Industry Opportunities and Challenges

Scope & coverage.

Types
  • Dasatinib
  • Bevacizumab
  • IMA-950
  • DCVax-L
  • CDX-1401
  • Alisertib
  • Others
Applications
  • ASCs
  • Hospital
  • Clinic
Companies covered
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co
  • Pfizer Inc
  • Tocagen Inc
  • Northwest Biotherapeutics Inc
  • Millennium Pharmaceuticals Inc
  • Leadiant Biosciences Inc
  • Ipsen SA
  • Immatics Biotechnologies GmbH
  • Celldex Therapeutics Inc
  • Cavion LLC
  • Bristol-Myers Squibb Co
  • Boehringer Ingelheim GmbH
  • AngioChem Inc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Oligodendroglioma Treatment Market Size (2021-2032)
  4. 2.2.2 Global Oligodendroglioma Treatment Sales (2021-2032)
  5. 2.2.3 Global Oligodendroglioma Treatment Market Average Price (2021-2032)
  6. 2.3 Oligodendroglioma Treatment by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Dasatinib
  9. 2.3.3 Bevacizumab
  10. 2.3.4 IMA-950
  11. 2.3.5 DCVax-L
  12. 2.3.6 CDX-1401
  13. 2.3.7 Alisertib
  14. 2.3.8 Others
  15. 2.4 Oligodendroglioma Treatment by Application
  16. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  17. 2.4.2 ASCs
  18. 2.4.3 Hospital
  19. 2.4.4 Clinic
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Oligodendroglioma Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Oligodendroglioma Treatment Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Oligodendroglioma Treatment Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Oligodendroglioma Treatment Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Oligodendroglioma Treatment Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Oligodendroglioma Treatment, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Oligodendroglioma Treatment, Product Type & Application
  8. 3.8 Global Manufacturers of Oligodendroglioma Treatment, Established Date
  9. 3.9 Global Oligodendroglioma Treatment Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Novartis AG
  2. 4.1.1 Novartis AG Company Information
  3. 4.1.2 Novartis AG Business Overview
  4. 4.1.3 Novartis AG Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Novartis AG Oligodendroglioma Treatment Product Portfolio
  6. 4.1.5 Novartis AG Recent Developments
  7. 4.2 F. Hoffmann-La Roche Ltd
  8. 4.2.1 F. Hoffmann-La Roche Ltd Company Information
  9. 4.2.2 F. Hoffmann-La Roche Ltd Business Overview
  10. 4.2.3 F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Product Portfolio
  12. 4.2.5 F. Hoffmann-La Roche Ltd Recent Developments
  13. 4.3 Eli Lilly and Co
  14. 4.3.1 Eli Lilly and Co Company Information
  15. 4.3.2 Eli Lilly and Co Business Overview
  16. 4.3.3 Eli Lilly and Co Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Eli Lilly and Co Oligodendroglioma Treatment Product Portfolio
  18. 4.3.5 Eli Lilly and Co Recent Developments
  19. 4.4 Pfizer Inc
  20. 4.4.1 Pfizer Inc Company Information
  21. 4.4.2 Pfizer Inc Business Overview
  22. 4.4.3 Pfizer Inc Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Pfizer Inc Oligodendroglioma Treatment Product Portfolio
  24. 4.4.5 Pfizer Inc Recent Developments
  25. 4.5 Tocagen Inc
  26. 4.5.1 Tocagen Inc Company Information
  27. 4.5.2 Tocagen Inc Business Overview
  28. 4.5.3 Tocagen Inc Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Tocagen Inc Oligodendroglioma Treatment Product Portfolio
  30. 4.5.5 Tocagen Inc Recent Developments
  31. 4.6 Northwest Biotherapeutics Inc
  32. 4.6.1 Northwest Biotherapeutics Inc Company Information
  33. 4.6.2 Northwest Biotherapeutics Inc Business Overview
  34. 4.6.3 Northwest Biotherapeutics Inc Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Northwest Biotherapeutics Inc Oligodendroglioma Treatment Product Portfolio
  36. 4.6.5 Northwest Biotherapeutics Inc Recent Developments
  37. 4.7 Millennium Pharmaceuticals Inc
  38. 4.7.1 Millennium Pharmaceuticals Inc Company Information
  39. 4.7.2 Millennium Pharmaceuticals Inc Business Overview
  40. 4.7.3 Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Product Portfolio
  42. 4.7.5 Millennium Pharmaceuticals Inc Recent Developments
  43. 4.8 Leadiant Biosciences Inc
  44. 4.8.1 Leadiant Biosciences Inc Company Information
  45. 4.8.2 Leadiant Biosciences Inc Business Overview
  46. 4.8.3 Leadiant Biosciences Inc Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Leadiant Biosciences Inc Oligodendroglioma Treatment Product Portfolio
  48. 4.8.5 Leadiant Biosciences Inc Recent Developments
  49. 4.9 Ipsen SA
  50. 4.9.1 Ipsen SA Company Information
  51. 4.9.2 Ipsen SA Business Overview
  52. 4.9.3 Ipsen SA Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Ipsen SA Oligodendroglioma Treatment Product Portfolio
  54. 4.9.5 Ipsen SA Recent Developments
  55. 4.10 Immatics Biotechnologies GmbH
  56. 4.10.1 Immatics Biotechnologies GmbH Company Information
  57. 4.10.2 Immatics Biotechnologies GmbH Business Overview
  58. 4.10.3 Immatics Biotechnologies GmbH Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Immatics Biotechnologies GmbH Oligodendroglioma Treatment Product Portfolio
  60. 4.10.5 Immatics Biotechnologies GmbH Recent Developments
  61. 4.11 Celldex Therapeutics Inc
  62. 4.11.1 Celldex Therapeutics Inc Company Information
  63. 4.11.2 Celldex Therapeutics Inc Business Overview
  64. 4.11.3 Celldex Therapeutics Inc Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Celldex Therapeutics Inc Oligodendroglioma Treatment Product Portfolio
  66. 4.11.5 Celldex Therapeutics Inc Recent Developments
  67. 4.12 Cavion LLC
  68. 4.12.1 Cavion LLC Company Information
  69. 4.12.2 Cavion LLC Business Overview
  70. 4.12.3 Cavion LLC Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Cavion LLC Oligodendroglioma Treatment Product Portfolio
  72. 4.12.5 Cavion LLC Recent Developments
  73. 4.13 Bristol-Myers Squibb Co
  74. 4.13.1 Bristol-Myers Squibb Co Company Information
  75. 4.13.2 Bristol-Myers Squibb Co Business Overview
  76. 4.13.3 Bristol-Myers Squibb Co Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Bristol-Myers Squibb Co Oligodendroglioma Treatment Product Portfolio
  78. 4.13.5 Bristol-Myers Squibb Co Recent Developments
  79. 4.14 Boehringer Ingelheim GmbH
  80. 4.14.1 Boehringer Ingelheim GmbH Company Information
  81. 4.14.2 Boehringer Ingelheim GmbH Business Overview
  82. 4.14.3 Boehringer Ingelheim GmbH Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Boehringer Ingelheim GmbH Oligodendroglioma Treatment Product Portfolio
  84. 4.14.5 Boehringer Ingelheim GmbH Recent Developments
  85. 4.15 AngioChem Inc
  86. 4.15.1 AngioChem Inc Company Information
  87. 4.15.2 AngioChem Inc Business Overview
  88. 4.15.3 AngioChem Inc Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 AngioChem Inc Oligodendroglioma Treatment Product Portfolio
  90. 4.15.5 AngioChem Inc Recent Developments
5 Global Oligodendroglioma Treatment Market Scenario by Region
  1. 5.1 Global Oligodendroglioma Treatment Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Oligodendroglioma Treatment Sales by Region: 2021-2032
  3. 5.2.1 Global Oligodendroglioma Treatment Sales by Region: 2021-2026
  4. 5.2.2 Global Oligodendroglioma Treatment Sales by Region: 2027-2032
  5. 5.3 Global Oligodendroglioma Treatment Revenue by Region: 2021-2032
  6. 5.3.1 Global Oligodendroglioma Treatment Revenue by Region: 2021-2026
  7. 5.3.2 Global Oligodendroglioma Treatment Revenue by Region: 2027-2032
  8. 5.4 North America Oligodendroglioma Treatment Market Facts & Figures by Country
  9. 5.4.1 North America Oligodendroglioma Treatment Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Oligodendroglioma Treatment Sales by Country (2021-2032)
  11. 5.4.3 North America Oligodendroglioma Treatment Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Oligodendroglioma Treatment Market Facts & Figures by Country
  16. 5.5.1 Europe Oligodendroglioma Treatment Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Oligodendroglioma Treatment Sales by Country (2021-2032)
  18. 5.5.3 Europe Oligodendroglioma Treatment Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Oligodendroglioma Treatment Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Oligodendroglioma Treatment Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Oligodendroglioma Treatment Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Oligodendroglioma Treatment Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Oligodendroglioma Treatment Market Facts & Figures by Country
  41. 5.7.1 South America Oligodendroglioma Treatment Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Oligodendroglioma Treatment Sales by Country (2021-2032)
  43. 5.7.3 South America Oligodendroglioma Treatment Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Oligodendroglioma Treatment Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Oligodendroglioma Treatment Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Oligodendroglioma Treatment Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Oligodendroglioma Treatment Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Oligodendroglioma Treatment Sales by Type (2021-2032)
  2. 6.1.1 Global Oligodendroglioma Treatment Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Oligodendroglioma Treatment Sales Market Share by Type (2021-2032)
  4. 6.2 Global Oligodendroglioma Treatment Revenue by Type (2021-2032)
  5. 6.2.1 Global Oligodendroglioma Treatment Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Oligodendroglioma Treatment Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Oligodendroglioma Treatment Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Oligodendroglioma Treatment Sales by Application (2021-2032)
  2. 7.1.1 Global Oligodendroglioma Treatment Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Oligodendroglioma Treatment Sales Market Share by Application (2021-2032)
  4. 7.2 Global Oligodendroglioma Treatment Revenue by Application (2021-2032)
  5. 7.2.1 Global Oligodendroglioma Treatment Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Oligodendroglioma Treatment Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Oligodendroglioma Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Oligodendroglioma Treatment Value Chain Analysis
  2. 8.1.1 Oligodendroglioma Treatment Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Oligodendroglioma Treatment Production Mode & Process
  5. 8.2 Oligodendroglioma Treatment Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Oligodendroglioma Treatment Distributors
  8. 8.2.3 Oligodendroglioma Treatment Customers
9 Global Oligodendroglioma Treatment Analyzing Market Dynamics
  1. 9.1 Oligodendroglioma Treatment Industry Trends
  2. 9.2 Oligodendroglioma Treatment Industry Drivers
  3. 9.3 Oligodendroglioma Treatment Industry Opportunities and Challenges
  4. 9.4 Oligodendroglioma Treatment Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst